In this study, researchers evaluated patients who had incomplete cCRT or experienced progression during or within 42 days of receiving cCRT, with an aim of identifying risk factors for these outcomes.
GlobalData on MSN
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it has submitted a Biologics ...
Deep-learning analysis of routine H&E slides accurately predicts key NSCLC driver mutations, supporting treatment in lung cancer care.
Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...
Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, in Advanced NSCLC ...
When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results